June 28 : The FDA declined to approve Eton Pharmaceuticalsdehydrated alcohol injection for the treatment of methanol poisoning, citing concerns related primarily to Chemistry Manufacturing and Controls. This is the second Complete Response Letter issued to Eton for this proposed treatment
Available from: Jett, L., Lger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., & Bridon, D
Towards precision medicine for hypertension: A review of genomic, epigenomic, and microbiomic effects on blood pressure in experimental rat models and humans
CagriSema vs Comparators Feature Receptor targets CagriSema Amylin/calcitonin + GLP-1 Tirzepatide (Zepbound) GIP + GLP-1 Semaglutide alone (Wegovy) GLP-1 Cagrilintide alone Amylin/calcitonin (DACRA) Feature Dosing frequency CagriSema Once weekly Tirzepatide (Zepbound) Once weekly Semaglutide alone (Wegovy) Once weekly Cagrilintide alone Once weekly Feature Maintenance dose CagriSema 2.4 mg + 2.4 mg Tirzepatide (Zepbound) Up to 15 mg Semaglutide alone (Wegovy) 2.4 mg Cagrilintide alone 2.4 mg (in REDEFINE arms) Feature Headline weight loss CagriSema 20.4% at 68 wks (REDEFINE 1, treatment-policy) Tirzepatide (Zepbound) Up to 22.5% at 72 wks (SURMOUNT-1, 15 mg arm) Semaglutide alone (Wegovy) 14.9% at 68 wks (REDEFINE 1 reference arm) Cagrilintide alone 11.5% at 68 wks (REDEFINE 1 reference arm) Feature FDA status (June 2026) CagriSema NDA filed Dec 2025
These effects typically resolve within the first week
10.1016/0166-4328(95)00012-I Behav
